Edgewise Therapeutics Inc (EWTX)
Edgewise Therapeutics - Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
Edgewise Therapeutics - Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General